Literature DB >> 26975727

JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.

G Barosi1, C Klersy2, L Villani1, E Bonetti1, P Catarsi1, V Poletto1, R Campanelli1, S Impera3, R Latagliata4, G Viarengo5, A Carolei1, M Massa1, M Musso6, A Crescimanno6, R P Gale7, V Rosti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26975727     DOI： 10.1038/leu.2016.45

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.

Authors:  Paola Guglielmelli; Giada Rotunno; Costanza Bogani; Carmela Mannarelli; Laura Giunti; Aldesia Provenzano; Sabrina Giglio; Matthew Squires; Viktoriya Stalbovskaya; Prashanth Gopalakrishna; Alessandro M Vannucchi
Journal:  Br J Haematol       Date:  2015-08-25       Impact factor: 6.998

2.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.

Authors:  G Barosi; G Viarengo; A Pecci; V Rosti; G Piaggio; M Marchetti; F Frassoni
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

4.  Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

Authors:  Ayalew Tefferi; Francisco Cervantes; Ruben Mesa; Francesco Passamonti; Srdan Verstovsek; Alessandro M Vannucchi; Jason Gotlib; Brigitte Dupriez; Animesh Pardanani; Claire Harrison; Ronald Hoffman; Heinz Gisslinger; Nicolaus Kröger; Juergen Thiele; Tiziano Barbui; Giovanni Barosi
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

5.  Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.

Authors:  Keyur P Patel; Kate J Newberry; Rajyalakshmi Luthra; Elias Jabbour; Sherry Pierce; Jorge Cortes; Rajesh Singh; Meenakshi Mehrotra; Mark J Routbort; Madan Luthra; Taghi Manshouri; Fabio P Santos; Hagop Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2015-06-29       Impact factor: 22.113

6.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

7.  Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

Authors:  Raajit Rampal; Fatima Al-Shahrour; Omar Abdel-Wahab; Jay P Patel; Jean-Philippe Brunel; Craig H Mermel; Adam J Bass; Jennifer Pretz; Jihae Ahn; Todd Hricik; Outi Kilpivaara; Martha Wadleigh; Lambert Busque; D Gary Gilliland; Todd R Golub; Benjamin L Ebert; Ross L Levine
Journal:  Blood       Date:  2014-04-16       Impact factor: 22.113

8.  JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.

Authors:  Isabelle Plo; Mayuka Nakatake; Laurent Malivert; Jean-Pierre de Villartay; Stéphane Giraudier; Jean-Luc Villeval; Lisa Wiesmuller; William Vainchenker
Journal:  Blood       Date:  2008-05-30       Impact factor: 22.113

9.  Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.

Authors:  Michael Medinger; Radek Skoda; Alois Gratwohl; Alexandre Theocharides; Andreas Buser; Dominik Heim; Stephan Dirnhofer; André Tichelli; Alexandar Tzankov
Journal:  Br J Haematol       Date:  2009-05-19       Impact factor: 6.998

10.  Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper.

Authors:  Giovanni Barosi; Alessandro M Vannucchi; Valerio De Stefano; Fabrizio Pane; Francesco Passamonti; Alessandro Rambaldi; Giuseppe Saglio; Tiziano Barbui; Sante Tura
Journal:  Leuk Res       Date:  2013-09-19       Impact factor: 3.156
View more
  23 in total

1.  MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53.

Authors:  Imayavaramban Lakshmanan; Shereen Salfity; Parthasarathy Seshacharyulu; Satyanarayana Rachagani; Abigail Thomas; Srustidhar Das; Prabin D Majhi; Rama Krishna Nimmakayala; Raghupathy Vengoji; Subodh M Lele; Moorthy P Ponnusamy; Surinder K Batra; Apar Kishor Ganti
Journal:  Clin Cancer Res       Date:  2017-02-14       Impact factor: 12.531

2.  Risk stratification in myelofibrosis: the quest for simplification.

Authors:  Laura C Michaelis
Journal:  Haematologica       Date:  2017-01       Impact factor: 9.941

Review 3.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

Review 4.  Mutational profiling in myelofibrosis: implications for management.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2019-10-19       Impact factor: 2.490

5.  Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.

Authors:  Prithviraj Bose
Journal:  Expert Opin Orphan Drugs       Date:  2019-09-24       Impact factor: 0.694

6.  RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features.

Authors:  Giacomo Coltro; Giada Rotunno; Lara Mannelli; Carmela Mannarelli; Sara Fiaccabrino; Simone Romagnoli; Niccolò Bartalucci; Enrica Ravenda; Eleonora Gelli; Emanuela Sant'Antonio; Mrinal M Patnaik; Ayalew Tefferi; Alessandro M Vannucchi; Paola Guglielmelli
Journal:  Blood Adv       Date:  2020-08-11

7.  Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.

Authors:  Douglas Tremblay; Ruben Mesa; Bart Scott; Sarah Buckley; Karisse Roman-Torres; Srdan Verstovsek; John Mascarenhas
Journal:  Blood Adv       Date:  2020-12-08

Review 8.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Authors:  Daniel Arthur Corpuz Fisher; Jared Scott Fowles; Amy Zhou; Stephen Tracy Oh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 8.786

9.  Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.

Authors:  Francesca Palandri; Giuseppe Alberto Palumbo; Massimiliano Bonifacio; Mario Tiribelli; Giulia Benevolo; Bruno Martino; Elisabetta Abruzzese; Mariella D'Adda; Nicola Polverelli; Micaela Bergamaschi; Alessia Tieghi; Francesco Cavazzini; Adalberto Ibatici; Monica Crugnola; Costanza Bosi; Roberto Latagliata; Ambra Di Veroli; Luigi Scaffidi; Federico de Marchi; Elisa Cerqui; Barbara Anaclerico; Giovanna De Matteis; Marco Spinsanti; Elena Sabattini; Lucia Catani; Franco Aversa; Francesco Di Raimondo; Umberto Vitolo; Roberto Massimo Lemoli; Renato Fanin; Francesco Merli; Domenico Russo; Antonio Cuneo; Maria Letizia Bacchi Reggiani; Michele Cavo; Nicola Vianelli; Massimo Breccia
Journal:  Oncotarget       Date:  2017-06-27

Review 10.  SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.